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Abstract
Stereotactic radiosurgery (SRS) delivered as either single-fraction or multi-fraction SRS (2–5 fractions) is frequently
employed in patients with residual or recurrent pituitary adenoma. The most common delivery systems used for SRS
include the cobalt-60 system Gamma Knife, the CyberKnife (CK) robotic radiosurgery system, or a modified conventional
radiotherapy machine (linear accelerator, LINAC). Tumor control and normalization of hormone hypersecretion have been
reported in 75–100 % and 25–80 % of patients, respectively. Hypopituitarism is the most commonly reported late
complication of radiation treatment, whereas other toxicities occur less frequently. We have provided an overview of the
recent available literature on SRS in patients with a pituitary adenoma. Critical aspects of pituitary irradiation, including
target delineation and doses to organs at risk, optimal radiation dose, as well as the long-term efficacy and toxicity of SRS
for either nonfunctioning or secreting pituitary adenomas are discussed. Single-fraction SRS represents an effective
treatment for patients with a pituitary adenoma; however, caution should be used for lesions > 2.5–3 cm in size and/or
involving the anterior optic pathway. Future studies will be necessary to optimize target doses and critical organ dose
constrains in order to reduce the long-term toxicity of treatments while maintaining high efficacy.
Keywords: Fractionated stereotactic radiotherapy, Radiosurgery, Pituitary adenoma, Acromegaly, Cushing’s disease, Target
delineation
Introduction
Conventional radiation therapy (CRT) has traditionally
been used in patients with residual or recurrent secret-
ing and nonfunctioning pituitary adenomas who have
failed prior medical management and/or surgery, result-
ing in a variable long-term tumor control of 87–95 % at
10 years [1–4], and normalization of elevated plasma
levels of growth hormone (GH) and adrenocorticotropic
hormone (ACTH) in up to 55 %, and 78 % of patients,
respectively [5–8]. Hypopituitarism occurs in 30–60 %
of patients 5–10 years after irradiation, while other tox-
icities, including radiation-induced optic neuropathy,
cerebrovascular accidents, and secondary tumors have
been reported in 0–5 % [9–12].
Stereotactic radiosurgery (SRS) is a sophisticated radi-
ation therapy technique that precisely delivers high dose
of irradiation in a single o few (2–5) fractions to well-
defined, small-to-moderate brain targets. SRS allows for
more precise target localization and accurate dose deliv-
ery as compared with CRT, resulting in a reduction of
the volume of normal brain tissue irradiated to high
radiation doses [13]. The techniques used for the treat-
ment of a pituitary adenoma involve the Gamma Knife
(GK) [14], the CyberKnife (CK) robotic radiosurgery sys-
tem [15, 16], or a modified conventional radiotherapy
machine (linear accelerator, LINAC) [17, 18]. Data from
literature report a tumor control after SRS up to 97 % at
5 years, with normalization of hormone hypersecretion
in more than 50 % of patients [19]. Hypopituitarism is
the most commonly reported late complication of treat-
ment, whereas other late radiation-induced complica-
tions are low. As high doses are delivered to the tumor
with the use of the stereotactic radiosurgical techniques,
an accurate delineation of target and surrounding nor-
mal brain structures becomes increasingly important to
minimize radiation-induced toxicity while maintaining
high tumor control.
We aimed to provide a critical review of the different
aspects of radiosurgical techniques for pituitary tumors,
including the delineation of target and critical organs,
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technical characteristics of the different types of SRS de-
livery systems, the optimal dose and fractionation for
nonfunctioning and secreting pituitary adenomas, and
the long-term efficacy and toxicity.
Methods and materials
A literature search was conducted in MEDLINE
PubMed that evaluated adults with pituitary adenomas.
The search focused on randomized, prospective and
retrospective studies published in English. The searches
were limited by date from January, 2000 to November,
2015 using a combination of medical subject headings
(MeSH) (“pituitary adenomas/radiosurgery” or “non-
functioning pituitary adenomas” or “acromegaly” or
“Cushing disease” or “prolactinomas”) and free text
terms (“toxicity” or “hypopituitarism” or “target delinea-
tion” or “radiosurgical dose” or “fractionated radiosur-
gery” or “organs at risk”). Articles were excluded from
the review if they: had a non-English abstract, were not
available through Pubmed, were pediatric series or case
studies involving less than 8 patients, or were duplicated
publications. To identify additional articles, the refer-
ences of articles identified through the formal searches
were scanned for additional sources. A total of 984 po-
tentially relevant studies were identified. Finally, 92 stud-
ies reporting the clinical outcomes of SRS for either
nonfunctioning or secreting pituitary adenomas with a
minimum follow-up of 1 year were selected and in-
cluded in the review.
Target delineation
Defining the optimal target volume for a pituitary aden-
oma represents a balance between minimizing
treatment-related toxicity while maintaining a high
tumor control. Current optimal imaging technique for
target delineation requires the use of precontrast and
postcontrast magnetic resonance imaging (MRI) se-
quences to improve the accuracy of target identification
and delineation. Contrast-enhanced 3D T1-weighted se-
quences with 1 mm thin slices are extremely useful for
accurate target delineation by allowing identification of
subtle enhancement patterns in the surrounding neuro-
vascular structures and along the course of the optic
nerve [20]. For planning purpose, MRI scan is subse-
quently fused with thin-slice non-contrast enahnaced
CT scan. Although a displacement up to 2.8 mm has
been reported for brain soft-tissue based fusion, the
magnitude of displacement is considered negligible for
lesions of the skull base due to its rigidity and great visi-
bility in all imaging modalities [21]; so far, no additional
margins would be required to ensure adequate target
coverage during SRS to compensate fusion uncertainties.
Since most pituitary adenomas are benign, slow-growing
neoplasms, peritumoral edema is generally absent. For
this reason, T2-weighted images, which are extremely
useful in evaluating the parenchyma of the brain and the
perilesional edema, are not generally used for target vol-
ume delineation. Preoperative MRI may be helpful to
discern postoperative changes from tumor, especially in
patients who had undergone several prior surgeries.
Similarly, contrast-enhanced T1-weighted images with
fat suppression may be used to minimize postoperative
changes that might obscure the accuracy of radiosurgical
targeting. when MRI is contraindicated, a thin-slice CT
imaging through the pituitary regions is performed with
and without contrast administration.
The gross tumor volume (GTV) is represented by the
lesion visible on MRI/CT. The clinical target volume
(CTV) includes microscopic disease. In general, add-
itional margin expansion from GTV to CTV is unneces-
sary in pituitary adenomas; however, a small margin may
be added in the intracavernous portion of aggressive ad-
enomas to encompass potential areas of microscopic
tumor infiltration. The planning tumor volume (PTV)
should take into account uncertainties of patient setup.
Currently, a similar sub-millimteric accuracy of target
positioning has been reported for frameless CK and
LINAC based systems (Novalis Tx) and frame based GK
SRS technology [14–18, 22, 23]. In most centers, a mar-
gin of 0–1 mm is generally used for GTV to PTV expan-
sion; however, due to the different commercial SRS
systems, each department should audit their setup re-
sults and apply the margins on the basis of their own
observations.
Organs at risk
The sellar and parasellar region is an anatomically com-
plex area including endocrine, nervous, and vascular
structures. The pituitary fossa comprises the pituitary
gland, which is composed of the adenohypophysis and
neurohypophysis. The parasellar region encompasses the
cavernous sinuses and the suprasellar cistern structures.
The cavernous sinus consists of trabeculated, multilobu-
lated venous channels which are located lateral to the
sella turcica and sphenoid sinus. The cavernous sinus
contains cranial nerves III (oculomotor), IV (trochlear),
V1 (ophthalmic division of the trigeminal nerve), V2
(maxillary division of the trigeminal nerve) and VI (ab-
ducens). It also contains the cavernous segment of the
internal carotid artery. The suprasellar cistern includes
the optic chiasm and nerves, the anterior third ventricle,
the hypothalamus, the pituitary infundibulum, the infun-
dibular and suprachiasmatic recesses of the third
ventricle.
A careful delineation of all organs at risk (OARs) sur-
rounding the target volume is mandatory. OARs in the
skull base region include optic nerves and chiasm, brain-
stem, pituitary stalk, pituitary gland, and cavernous sinus
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cranial nerves (an example of GTV and OARs contours
is shown in Figs. 1 and 2). Expansion of OARs to create
a planning risk volume (PRV) for each OAR may be ap-
plied; the margin, as for the GTV, should reflect the ac-
curacy of daily set-up. Overlaps between PRVs and PTV
should be considered; however, caution should be used
when the reduction of the dose to the OARs may results
in inadequate dose coverage of PTV. With regard to
dose limits for the OARs, the optic nerves and chiasm
are believed to be the most radiation-sensitive structures
to SRS. A risk of radiation-induced optic neuropathy up
to 2 % has been reported for point doses to the optic
pathway of 8–10 Gy [24–31]; however, the risk of optic
neuropathy remains low for point doses of 10–12 Gy to
small portions of the optic apparatus [25, 27, 29, 30]. In
a retrospective series of 222 patients who received GK
SRS for benign tumors adjacent to the anterior visual
pathway, Leavitt et al. [29] observed no new visual
Fig. 1 Target delineation of a pituitary adenoma. Gross tumor volume/Planning target volume (GTV/PTV) and organs at risk are outlined as solid
lines. GTV/PTV (red); optic chiasm (yellow); left optic nerve (orange); right optic nerve (cyan); letf lens (light yellow); right lens (light blue);
brainstem (green); pituitary stalk (blue); pituitary gland (pink); right hippocampus (purple); left hippocampus (golden yellow)
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symptoms for patients receiving a maximum dose of
12 Gy to small portions (2–4 mm3) of the optic chiasm
after single-fraction SRS. The risk of developing
radiation-induced optic neuropathy was 0 for patients
receiving a maximum point dose of 8–12 Gy and 10 %
for those receiving a maximum point dose of 12–15 Gy
to the anterior optic pathway. Hasegawa et al. [27] evalu-
ated 100 patients undergoing GK SRS for craniopharyn-
giomas. Two patients who received maximum radiation
point doses to the optic pathway of 15 and 18 Gy, re-
spectively, developed optic neuropathy, whereas no vis-
ual deficits were observed in patients receiving lower
doses. While these studies suggest that point doses up to
12 Gy to small portion of the optic pathway are associ-
ated with a low risk of optic neuropathy, in clinical prac-
tice a maximum point dose of 10 Gy is usually
recommended when treating lesions adjacent to the
optic pathway.
Little is known about the tolerance of the cranial
nerves of the cavernous sinus. Leber et al. [25] reported
no cranial nerve injury in patients receiving single-
fraction SRS when doses of 5–30 Gy were delivered to
the cavernous sinus. In contrast, Tishler et al. [24] re-
ported a 13 % incidence of the third and sixth cranial
nerve in 62 patients undergoing GK SRS; however, they
could not find a significant relationship between the de-
livered dose of 10–40 Gy and new or worsening deficits.
Although a precise tolerance dose of cranial nerves
within the cavernous sinus after single-fraction SRS can-
not be defined, doses up to 18 Gy to the cavernous sinus
are associated with low incidence of radiation-induced
toxicity (0–4 %) [13, 32].
Hypopituitarism is the most common adverse effect
after SRS for a pituitary adenoma. Several studies have
evaluated the relationship between radiation doses to the
normal pituitary gland and distal infundibulum [33–38]
and the development of hypopituitarism. Leenstra et al.
[35] reported on 82 patients with either nonfunctioning
or secreting pituitary adenomas who received GK SRS at
the Mayo Clinic. Applying the criteria of a mean dose of
15 Gy to the pituitary gland, they noted new endocrine
deficits in 12 of 40 patients (30 %) for doses < 15 Gy
compared with 9 of 20 patients (45 %) who received a
mean gland dose > 15 Gy. In their analysis they found
new anterior deficits in 0 %, 29 %, 39 % and 83 % for
mean doses to the pituitary gland ≤ 7.5Gy, 7.6–13.2 Gy,
13.3–19.1 Gy, and > 19.1 Gy, respectively. In another
series of 85 patients treated with GK for a pituitary ad-
enoma, Marek et al. [36] reported an incidence of hypo-
pituitarism of 2.2 % for patients irradiated with a mean
dose to pituitary < 15 Gy and 72.5 % for those who re-
ceived a mean dose > 15 Gy. A significant correlation be-
tween the mean dose of 15 Gy to the pituitary gland and
the development of new pituitary deficits has been re-
ported in other studies [34, 38].
The correlation between the mean dose delivered to
the pituitary stalk and the incidence of hypopituitarism
has been evaluated in retrospective series [33, 34, 36,
38]. In a series of 130 patients treated with single-
fraction SRS, Sicignano et al. [38] reported 5-year actu-
arial incidence of new pituitary deficits of 8 % for a
mean dose to the pituitary stalk < 7.3 Gy and 32 % for a
mean dose to the pituitary stalk > 7.3 Gy. Similarly, Feigl
et al. [33] observed a significant incidence of new endo-
crine deficits for doses > 6.5 Gy to the pituitary stalk in a
series of 108 patients treated with GK SRS for a pituitary
adenoma. In contrast, Vladika et al. [34] found a signifi-
cant incidence of new pituitary deficits after single-
fraction SRS only for patients who received a maximum
dose to the pituitary stalk > 17 Gy. Future prospective
studies with an appropriate follow-up will be necessary
to better identify the maximum safe doses to the pituit-
ary gland and the pituitary stalk. Whenever possible,
mean radiation doses to the pituitary gland and stalk
should be kept under 12–15 Gy and 7–10 Gy, respect-
ively, with the aim of limiting the development of new
pituitary deficits.
Other OARs include the brainstem and hippocampi.
For single fraction SRS, maximum brainstem doses of
12–14 Gy are associated with low (<5 %) risk of
neurological complications, although this risk signifi-
cantly increases for doses > 15 Gy given as single fraction
Fig. 2 Axial, coronal, and sagittal view of target delineation for a pituitary adenoma. For GTV,PTV and organs at risk, see Fig. 1
Minniti et al. Radiation Oncology  (2016) 11:135 Page 4 of 14
[28, 39]. In a recent review of radiation associated brain-
stem toxicity, Mayo et al. [28] calculated a risk of normal
tissue complication probability of 1 %, 13 %, 61 %, and
94 % for partial volume irradiation of one third of the
brainstem to doses of 12.5, 14.2, 16, and 17.5 Gy, re-
spectively. A lower risk of complications was observed
when the same doses were delivered to a small partial
volume (1 %) of the brainstem. Although definitive cri-
teria of dose-volume effects on brainstem dose tolerance
after single-fraction SRS remains to be better defined, in
clinical practice caution should be used when delivering
doses to the brainstem > 12.5 Gy. For tumors located in
the parasellar region, hippocampi can be contoured as
an effort to reduce the potential negative neurocognitive
effect of high radiation doses to the hippocampal region
[40]; the principle of this approach is acknowledged but
there is currently insufficient evidence to support rec-
ommendations on hippocampal sparing during SRS.
There is limited evidence relating tolerance of the
optic apparatus and cranial nerves of the cavernous
sinus after multi-fraction SRS. Retrospective studies have
observed a risk of optic complications of less than 1 %
for patients with skull base tumors treated with doses of
21–25 Gy delivered in 3–5 fractions [41–46]. Liao et al.
[45] reported the outcome of fractionated SRS delivered
with a LINAC system. Thirty-four residual/recurrent pi-
tuitary adenomas with a median tumor volume of
4.11 cm3 in close proximity to the optic apparatus (me-
dian minimal distance 1 mm, ranging from 0 to 2.5 mm)
were treated with a total dose fo 21 Gy in 3 fractions of
7 Gy each. With a median follow-up of 37 months, no
patients developed optic neuropathy; the mean single-
fraction doses to the optic nerve and chiasm were 5.58
± 0.98 and 4.86 ± 0.15 Gy, respectively. One patients de-
veloped transient diplopia after SRS, which resolved after
a short course of dexamethasone. Using doses of 21 Gy
in 3 fractions or 25 Gy in 5 fractions delivered with CK,
Iwata et al. [44] reported a grade 2 visual disorder in
only 1 out of 100 patients at a median follow-up of
33 months; however, no details of doses delivered at
optic apparatus were provided in their study. In another
study of 34 patients who received a multifraction SRS (5
× 5 Gy) at University of Rome Sapienza for a skull base
metastasis involving the anterior optic pathway, at a me-
dian follow-up of 13 months no optic neuropathy were
observed for doses >25 Gy to less than one-third of optic
chiasm and > 27.5 Gy to a small volume of 0.01–
0.06 cm3 [46]. With regard to the cavernous sinus cra-
nial nerves tolerance, no deficits have been reported
using median doses of 20 Gy delivered in 2 to 5 fractions
for perioptic lesions [41–43]. Although these studies in-
dicate that 5 × 5 Gy or 3 × 7 Gy schedules are associated
to a low risk of radiation-induced optic neuropathy and
cavernous sinus cranial deficits, further studies need to
better evaluate the dose-volume relations for OARs dur-
ing multi-fraction SRS of patients with pituitary tumors.
Treatment techniques
SRS for pituitary adenomas is typically delivered as
single-fraction SRS or, less frequently, as multi-fraction
SRS (2–5 fractions). Main used techniques include the
use of GK, CK or a modified LINAC [13–18]. In its new
version, GK uses 192 radioactive cobalt-60 sources that
are spherically arrayed in a single internal collimation
system via collimator helmets to focus their beams to a
center point. The tungsten collimators are organized
into eight sectors of 24 sources each with three different
apertures of 4 mm, 8 mm, and 16 mm, respectively. A
highly conformal but inhomogeneous dose distribution
and high central tumor dose can be achieved through
the optimal combinations of the number, the aperture
and the position of the collimators [14, 15, 22]. Trad-
itionally, patients are placed in a rigid stereotactic frame
achieving submilimeter accuracy in dose delivery. The
dose is typically prescribed at the 50 % isodose to obtain
the maximum dose at the center of each pinpointed tar-
get and the prescribed dose at target edge.
CK (Accuray, Sunnyvale, CA) is a relatively new
technological device that combines a mobile linear accel-
erator mounted on a robotic arm with an image-guided
robotic system [15, 16, 23, 47]. Patients are fixed in a
thermoplastic mask and the treatment can be delivered
as single-fraction or multi-fraction SRS. A variable num-
ber of overlapping beams (up to 200) are delivered non-
isocentrically to the target, resulting in excellent dose
coverage to the target and conformity. The set of beam
directions and analysis of dose distribution are chosen
through an inverse planning process. During the tr-
eatment, acquired oblique digital X-ray images of the
patients are compared with digitally reconstructed radio-
graphs (DRRs), which are obtained from planning CT
images, and positioning errors corrected by translating
and rotating the treatment table with an accuracy of less
than 1 mm [15, 16].
LINAC is the most frequently used device for delivery
SRS in the world and uses multiple fixed fields or arcs
shaped using a multileaf collimator with a leaf width of
between 2.5 and 5 mm [17, 18, 48–51]. Dose conformity
can be improved by the use of intensity modulation of
the beams (IMRS) or volumetric modulated arc therapy
(VMAT), resulting similar to that achieved with the GK
and the CK. Patients are usually immobilized in a high
precision frameless stereotactic mask fixation system
with a reported accuracy of 1–2 mm [48]; however, tech-
nically most advanced LINACs offer improved accuracy
of patient repositioning with the use of on-board im-
aging systems with either orthogonal x-rays or cone
beam CT (CBCT) that achieves an accuracy of less than
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0.5–1 mm [17, 18, 50, 51]. The ExacTrac®X.ray 6D sys-
tem uses a combination of two main subsystems: an
infrared-based system for initial patient setup and pre-
cise control of either translational or rotational couch
movements, and a radiographic kV X-ray imaging sys-
tem for position verification and readjustment based on
internal anatomy. A CBCT system utilizes either the
megavoltage radiation beam delivered from the LINAC
or a kilovoltage beam delivered using an additional x-ray
tube mounted on the LINAC. During a single 360° scan
rotation, the system produces a series of two-
dimensional images of the entire volume of interest from
multiple projection angles, which can be reconstructed
in a three-dimensional data that can be directly com-
pared with the CT planning study.
The superiority in terms of dose delivery and distribu-
tion for each of these techniques remains matter of de-
bate. Despite several differences in treatments-related
parameters among GK, CK and LINAC, there are no
comparative studies demonstrating the clinical superior-
ity of a technique over the others in terms of local
control and radiation-induced toxicity for patients with
brain tumors. Regardless of the technology used, a ro-
bust quality assurance (QA) program, encompassing all
clinical, technical, and patient-specific treatment aspects,
is mandatory to ensure the accuracy and safety of cranial
SRS [52]. As stated by The World Health Organization,
proper QA measures are imperative to reduce the likeli-
hood of accidents and errors and increase the probability
that the errors will be recognized and rectified if they do
occur [52]. For brain SRS, detailed equipment specifica-
tions and tolerances, as well procedures that minimize
the risk of errors and incidents have been reported by
several professional organizations [52–57].
Clinical results
Nonfunctioning pituitary adenomas
SRS is frequently used in patients with residual or recur-
rent nonfunctioning pituitary adenoma. Data for 1965
patients with a nonfunctioning pituitary adenoma in-
cluded in 23 studies published between 2002 and 2015
are shown in Table 1 [32, 58–78]. SRS was performed
Table 1 Selected published results of SRS (2000–2015) for the treatment of nonfunctioning pituitary adenomas
Authors Patients Type dose Follow-up Tumor Late toxicity (%)
of SRS (Gy) (months) control (%) visual hypopituitarism
Feigl et al., 2002 [33] 61 GK 15a 55.2 94 NA 40
Sheehan et al., 2002 [58] 42 GK 16a 31.2 97.6 2.4 0
Wowra & Stummer, 2002 [59] 30 GK 16a 55 93.3 (93 at 5 years) 0 10
Petrovich et al., 2003 [60] 56 GK 15a 36 100 3 4
Losa et al., 2004 [61] 52 GK 16.6a 41 96.3 (88.2 at 5 years) 0 9.3
Muacevic et al., 2004 [62] 51 GK 16.5a 21.7 95 0 3.9
Picozzi et al., 2005 [63] 51 GK 16.5a 40.6 96.1 NA NA
Iwai et al., 2005 [64] 34 GK 12.3a 59.8 87.1 (93 at 5 years) 0 6.5
Mingione et al., 2006 [65] 100 GK 18.5a 44.9 92.2 0 19.7
Voges et al., 2006 [66] 37 LINAC 13.4 56.6 100 1.4 12.3
Liscak et al., 2007 [67] 140 GK 20a 60 100 0 2
Pollock et al., 2008 [68] 62 GK 16a 64 96.8 (95 at 5 years) 0 27
Kobayashi et al., 2009 [69] 71 GK 14.1a 50.2 96.7 2.8 8.2
Hayashi et al., 2010 [70] 43 GK 18.2a 36 100 0 0
Gopalan et al., 2011 [71] 48 GK 18.4a 95 83.3 0 39
Iwata et al., 2011 [44] 100 CK 3×7/5×5 33 98 1 3
Park et al., 2011 [72] 125 GK 13a 62 90 (94 at 5 years) 0,8 24
Starke et al., 2012 [73] 140 GK 18a 50 89.6 (97 at 5 years) 0 30.3
Runge et al., 2012 [74] 61 LINAC 13 83 98 0 9.8
Wilson et al., 2012 [75] 51 LINAC 14 50 100 0 0
Sheehan et al., 2013 [76] 512 GK 16a 36 93.4 (95 at 5 years) 7.9 21
Lee et al., 2014 [77] 41 GK 12a 48 92.7 (85 at 10 years) 2.4 24.4
Bir et al., 2015 [78] 57 GK 15a 45.5 93 (90 % at 10 years) 0 8.8
SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
amarginal dose
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with GK in 19 studies, LINAC in 3 studies, and CK in
one study. With a median follow-up ranging from
21.7 months to 95 months (average 47.3 months), tumor
control was seen in 94 % of patients using a median pre-
scription dose of 16 Gy (range 12–20 Gy). In 9 studies
including 1053 patients with nonfunctioning pituitary
adenoma, 5-year Kaplan-Meier local control estimate
was 92 % [59, 61, 64, 68, 72, 73, 76–78] (Table 1). A de-
crease in tumor size has been reported in 20–60 % of
patients. With regard to factors predicting local control
after SRS, smaller tumor volumes (<5 cm3) and limited
suprasellar extension were associated with improved
local control [68, 72, 73, 76].
There is no consensus about the timing of SRS for
nonfunctioning pituitary adenomas. Early postoperative
SRS treatment has been suggested by some authors to
decrease the rate of tumor progression and symptomatic
endocrinophaty of subtotally resected nonfunctioning pi-
tuitary adenomas as compared with late SRS [63, 79]; in
contrast, a policy of surveillance may be observed in
older patients with small residual tumors for the low in-
cidence of symtomatic recurrences following subtotal
tumor resection [80].
New or worsened hormone pituitary deficits were
the most common complication after SRS, with a me-
dian incidence of hypopituitarism of 18 % at median
follow-up of 47 months [32, 58–78] (Table 1); neuro-
logical complications, including worsening of vision
or other cranial nerve deficits, were less common
(average 2.4 %, range 0–7.9 %).
Radiation doses used for patients with nonfunctioning
adenomas treated with SRS are shown in Table 1. Me-
dian dose prescription was 12–14 Gy in 6 studies [64,
66, 72, 74, 75, 77], 14.1–16 Gy in 8 studies [32, 58, 59,
68, 69, 76, 78], and > 16 Gy in 7 studies [61–63, 65, 67,
70, 71, 73] including 349, 891, and 625 patients, respect-
ively. Median tumor control rates were 93 % for doses of
12–14 Gy (median follow-up 61 months), 95 % for doses
of 14.1–16 Gy (median follow-up 41 months), and 94 %
for doses > 16 Gy (median follow-up 50 months). In a
retrospective multicenter clinical trial of 512 patients
treated with GK SRS, Sheehan et al [76] showed that
margin doses < 12 Gy were significantly associated with
worse control rate as compared with doses of 12–20 Gy,
whereas no significant difference in tumor control rates
have been observed between patients treated with 12–
20 Gy versus those receiving doses > 20 Gy. Similar re-
sults have been reported by others [65, 71–73, 76].
Multi-fraction SRS (2–5 fractions) has been employed
in patients with tumors involving the optic apparatus
who are considered not suitable for SRS [44, 81–83].
Using doses of 18–24 Gy delivered in two to five ses-
sions with Cyberknife, Adler et al. [81] reported a tumor
control of 94 % in 46 patients with a pituitary adenoma
or meningioma within 2 mm of the optic apparatus at a
median follow-up of 49 months. A case of radiation
optic neuropathy was observed in one patient who
had a previous course of conventional RT. Iwata et al.
[44] reported a local control rate of 98 % at 3 years
in 100 patients with nonfunctioning pituitary aden-
omas treated with CK SRS using doses of 21 in 3
fractions or 25 Gy in 5 fractions. Complications were
represented by grade 2 visual disorders in one patient
and new onset of hypopituitarism in 4 patients. Simi-
lar tumor control and low toxicity have been reported
in other few series [45, 82, 83].
GH-secreting pituitary adenomas
SRS is commonly used in patients with a GH-secreting
pituitary adenoma failing surgery and/or resistant to
medical therapy. Data from 32 studies on SRS including
1802 patients with GH-secreting pituitary adenomas
show median weighted tumor control and biochemical
control of disease rates of 95 % and 44 %, respectively, at
a median follow-up of 59 months (Table 2) [36, 37, 66,
70, 82, 84–110]. GK SRS is the most used technique,
with a reported biochemical remission of 46 % at a me-
dian follow-up of 58 months. Four studies report results
of LINAC SRS, 2 studies report results of proton SRS,
and one study report results of CK SRS for GH-
secreting tumors, showing a biochemical remission of
disease ranging from 19 to 68 % at a median follow-up
of 62 months.
The variable rate of hormone normalization observed
in the different series may depend, at least in part, by
different criteria used to define GH/IFG-1 plasma levels
normalization, different follow-up times, pre-irradiation
GH/IGF-1 levels and concomitant medical therapies,
making difficult the interpretation of published results
and the real efficacy of SRS. Nevertheless, using strin-
gent criteria of cure, as defined by suppressed GH levels
< 1 ng/ml during an oral glucose tolerance test (OGTT)
and normal age-corrected IGF-1 levels, the Kaplan-
Meier estimate of local control reported in 10 studies in-
cluding 700 patients was 52 % at 5 years [66, 91, 93, 94,
96, 97, 99, 103, 108, 109] (Table 2), and normalization of
GH/IGF-1 levels continued throughout the follow-up
period.
A variable median dose prescription of 14 to 31 Gy
has been used in the published series [36, 37, 66, 70, 82,
84–110] (Table 2). Median doses were < 20 Gy in 4
studies [66, 87, 90, 105], 20–25 Gy in 21 studies
[85,8689,92,93,95–99,102–104,106–110], and > 25 Gy in
6 studies [84, 88, 91, 94, 100, 101] that include 216,
1196, and 390 patients, respectively (Table 2). Biochem-
ical remission was 31 % for doses < 20 Gy (median
follow-up 55 months), 47 % for doses of 20–25 Gy
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(median follow-up 60 months), and 33 % for doses >
25 Gy (median follow-up 59 months).
Although early reports suggest that the decline in GH
levels after GK SRS is faster compared with fractionated
RT [111, 112], the rate of decline observed in most re-
cent series is similar to that reported following fraction-
ated RT [86, 91, 93, 96, 100, 103]. The rate of decline
mainly depends on pretreatment levels of GH and IGF-1
levels. Losa et al. [96] reported a median time for remis-
sion of 37 months for patients with pretreatment GH
levels ≤ 7 μg/liter as compared with 93 months for
patients with GH levels > 7 μg/liter. In another retro-
spective analysis of 46 patients, the 5-year biochemical
remission rates 90 % for patients with IGF-1 levels less
than 2.25 times the upper limit of normal and 38 % for
those with IGF-1 levels greater than 2.25 times the
upper limit of normal, respectively [93].
Cushing disease
SRS data for 706 patients with Cushing’s disease in-
cluded in 21 studies are shown in Table 3 [35, 37, 66, 69,
70, 92, 98, 105, 109, 113–123]. Biochemical remission of
Table 2 Selected published results of SRS (2000–2015) for the treatment of GH-secreting pituitary adenomas
Authors Patients Type Dose Follow-up Tumor Biochemical Late toxicity (%)
of SRS (Gy) (months) control (%) remission (%) visual hypopituitarism
Zhang et al., 2000 [84] 68 GK 31a 34 100 40 NA NA
Izawa et al., 2000 [85] 29 GK 22.5a 26.4 93 41 0 0
Attanasio et al., 2003 [86] 30 GK 20a 46 100 23 0 6.3
Jane et al., 2003 [87] 64 GK 15a > 18 100 36 0 28
Castinetti et al., 2005 [88] 82 GK 28.5a 49.5 100 17 1.2 16
Gutt et al., 2005 [89] 44 GK 23a 23 100 48 0 NA
Kobayashi et al., 2005 [90] 67 GK 18.9a 63.3 100 17 11.1 14.6
Jezkova et al., 2006 [91] 96 GK 35a 53.7 100 50 (44 at 5 years) 0 27.1
Voges et al., 2006 [66] 64 LINAC 16.5 54.3 97 37.5 (33 at 5 years) 1,4 12.3 (18 at 5 years)
Petit et al., 2007 [92] 22 Protons 20 75 95 59 0 38
Pollock et al., 2007 [93] 46 GK 20a 63 100 50 (60 at 5 years) 2.2 36
Roberts et al., 2007 [82] 9 CK 18–24a 25.4 100 44.4 0 33
Vik-Mo et al., 2007 [94] 61 GK 26.5a 66 100 38 (58 at 5 years) 0 23
Jagannathan et al., 2008 [95] 95 GK 22a 57 98 53 4.2 34
Losa et al., 2008 [96] 83 GK 21.5a 69 97.6 60 (52 at 5 years) 0 8.5 (11.8 at 5 years)
Ronchi et al., 2009 [97] 35 GK 20a 114 100 82 (46 at 10 years) 0 50
Wan et al., 2009 [98] 103 GK 21.4a 67.3 95.1 36.9 NA 1.7
Hayashi et al., 2010 [70] 25 GK 25a 36 100 40 0 0
Iwai et al., 2010 [99] 26 GK 20a 84 96 38 (17 at 5 years) 0 8
Castinetti et al., 2009 [100] 43 GK 26a 96 100 42,0 0 23
Poon et al., 2010 [101] 40 GK 29a 73.8 NA 17 0 11.4
Erdur et al., 2011 [102] 22 GK 23.8a 60 95,2 54,5 0 28.6
Sheehan et al., 2011 [36] 130 GK 24a 31 93 53 2.3 34
Sicignano et al., 2012 [37] 39 GK 25a 60 97.7 54 NA 12.3
Franzin et al., 2012 [103] 103 GK 22.5a 71 97,3 60.7 (57 at 5 years) 0 7.8
Liu et al., 2012 [104] 40 GK 21a 72 97,5 47,5 0 40
Zeiler et al., 2013 [105] 21 GK 14.2a 33 100 30 3.9 13.2
Yan et al., 2013 [106] 22 LINAC 23 98 95 68.2 0 22.7
Wilson et al., 2013 [107] 86 LINAC 20 66 96 18.6 1,2 19.8
Lee et al., 2014 [108] 136 GK 25a 61.5 98.5 65.4 (73.4 at 6 years) 3.7 31.6
Wattson et al., 2014 [109] 50 Protons 20 51.5 100 48 (49 at 5 years) 0 57 (62 at 5 years)
Bostrom et al., 2015 [110] 21 LINAC 20 96 97.1 23 5 46.4
SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
amarginal dose; ^1–3 fractions
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disease was reported from 25 % to 80.7 % of patients
at a variable median follow-up of 2 to 17 years, with
median tumor control rates ranging from 87 % to
100 %. At a weighted average follow-up of 56 months,
the median tumor control was 95 % and biochemical
remission of disease, as measured by normalization of
24 h urinary free cortisol (UFC) and/or plasma corti-
sol levels, was 48 %.
The median time to hormone normalization ranges
from 12 to 25 months [35, 115, 116, 122]. In a retro-
spective series of 96 patients with Cushing’s disease
treated by GK SRS at the University of Virginia, Sheehan
et al. [122] reported a tumor control and biochemical re-
mission rates of 98 % and 70 %, respectively, with a time
to normalization of 16.6 months. New or worsened
hypopituitarism occurred in 36 % of patients and pro-
gressive or new onset optic neuropathy occurred in
4.5 % of patients. In another series of 40 patients with
Cushing’s disease treated by GK SRS, Castinetti et al.
[116] reported the biochemical remission of disease in
42.5 % of patients at a mean follow-up of 54 months,
with a mean time to hormone normalization of
22 months. Similar remission rates have been shown in
other retrospective series [35, 115, 122] (Table 3). A
recurrence rate up to 20 % after an initial remission of
disease has been reported in some series [115, 116, 122,
123], indicating that a careful follow-up is mandatory
also in patients who achieve normal hormone levels.
A median prescription dose of < 20 Gy has been used
in 4 studies including 77 patients [66, 115, 118, 120], of
20 to 25 Gy in 11 studies including 487 patients [37, 85,
92, 98, 105, 109, 113, 117, 119, 122, 123], and > 25 Gy in
6 studies including 142 patients [35, 70, 114, 116, 121]
(Table 3). The reported biochemical remission of disease
was similar, being 53 % for doses < 20 Gy (median
follow-up 40 months), 54 % for doses of 20–25 Gy (me-
dian follow-up 46 months), and 47 % for doses > 25 Gy
(median follow-up 62 months), and with respective
tumor control of 90 %, 98 %, and 95 %; however, in a
few studies a higher margin radiation dose of 25 Gy was
significantly associated with better biochemical remis-
sion of disease [117].
Prolactinomas
SRS is usually reserved for prolactinomas resistant to
medical therapy with dopamine agonists. Data for 610
patients with a prolactin-secreting pituitary adenoma in-
cluded in 17 studies published between 2000 and 2015
Table 3 Selected published results of SRS (2000–2015) for the treatment of ATCH-secreting pituitary adenomas
Authors Patients Type dose Follow-up Tumor Biochemical Late toxicity (%)
of SRS (Gy) (months) control (%) remission (%) visual hypopituitarism
Izawa et al., 2000 [85] 12 GK 23.8a 26.4 100 17 NA 0
Sheehan et al., 2000 [113] 43 GK 20a 44 100 63 2 16
Hoybye et al., 2001 [114] 18 GK >25a 17 years 100 83 0 66
Devin et al., 2004 [115] 35 LINAC 14.7 35 91 49 0 40
Voges et al., 2006 [66] 17 LINAC 16.4 58.7 82.4 52.9 1.4 12.3
Castinetti et al., 2007 [116] 40 GK 29.5a 54.7 100 42.5 2.5 15
Jagannathan et al., 2007 [117] 90 GK 25a 45 96 54 5.5 22
Petit et al., 2007 [92] 33 Protons 20 62 94 52 0 52
Pollock et al., 2008 [118] 8 GK 18a 54 100 87 0 36
Tinnel et al., 2008 [119] 12 GK 25a 37 83.3 50 0 50
Wan et al., 2009 [98] 68 GK 23a 67.3 89.7 27.9 2.9 1.7
Kobayashi et al., 2009 [120] 30 GK 28.7a 64.1 100 35 NA NA
Hayashi et al., 2010 [70] 13 GK 25.2a 36 97 38 15.4 0
Sicignano et al., 2012 [37] 15 GK 23.8a 60 97.7 64 NA 12.3
Wein et al., 2012 [120] 17 LINAC 18 23 94.1 58.8 0 11.8
Zeiler et al., 2013 [105] 8 GK 24.7a 35 100 50 3.9 13.2
Grant et al., 2013 [121] 15 GK 35a 40.2 100 73 3.2 32
Sheehan et al., 2013 [122] 96 GK 22a 48 98 70 5 36
Wattson et al., 2014 [109] 74 Protons 20 47 98.6 67at 5 years 0 62 at 5 years
Wilson et al., 2014 [123] 36 LINAC 20 66 97 25 0 13.9
Marek et al., 2015 [35] 26 GK 29a 78 91.9 80.7 0 11.5
SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed\
amarginal dose
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are shown in Table 4 [32, 36, 60, 66, 85, 98, 100, 109,
118, 124–131]. SRS was performed with GK in 15 stud-
ies, with LINAC in one study, and with protons in one
study. With a median follow-up ranging from 25 months
to 75.5 months (average 49 months), tumor control and
biochemical remission rates were reported for 95 % and
44 % of patients using median doses of 15 to 33 Gy.
The rate of normalization of prolactin levels was simi-
lar for patients treated with doses < 20 Gy (5 studies, 86
patients) [32, 60, 118, 127, 130], 20–25 Gy (7 studies,
305 patients) [36, 66, 85, 98, 109, 129, 131], and > 25 Gy
(5 studies, 219 patients) [100, 124–126, 128] (Table 4).
With median follow-ups of 50, 61, and 70 months, bio-
chemical remission rates were 40 %, 23 %, and 38 % for
doses < 20 Gy, 20–25 Gy, and > 25 Gy, respectively.
Complications
Based on the available published series, the overall rate
of serious complications after SRS is low. The mainly re-
ported complication is the development of hypopituitar-
ism, with 5-year incidence of new or worsening pituitary
deficits of 24 % (range from 10 to 40 %) [34, 61, 64, 66,
68, 72–78, 91, 93–97, 99, 103, 108, 109, 116, 118, 127,
129]. Rates of hypopituitarism are similar among non-
functioning and secreting pituitary adenomas. Factors
related to higher risk of hypopituitarism include pre-
existing anterior pituitary deficits, larger tumor volumes,
higher doses delivered to the pituitary gland and to the
pituitary stalk, and longer follow-up [34–37]. However,
hypopituitarism can be effectively managed with hormo-
nal replacement, and significant reduction of the pre-
scribed dose to prevent hypopituitarism with the risk of
compromising effectiveness of treatment in terms of
local control and normalization of hormonal hypersecre-
tion is not recommended. The risk of radiation-induced
optic neuropathy is 0–3 % for single point doses less
than 8–10 Gy to the optic apparatus [24–30]. Neur-
opathy of cranial nerves III–VI and radiation-induced
brain necrosis have been reported in less than 2 % of pa-
tients, with higher risk for those who received previous
conventional radiotherapy. The risk to develop a second
brain tumor after SRS appears to be significantly less
than that seen following conventional RT [11]; however
the relatively short length of follow-up in several pub-
lished series (< 5 years) does not allow for any definitive
conclusion.
Conclusions
SRS is an effective treatment modality for patients with
pituitary adenomas after unsuccessful surgery and/or re-
sistant to medical therapy. Doses of 13–16 Gy are usu-
ally employed for nonfunctioning pituitary adenomas
with a reported tumor control of 85–95 % at 5–10 years,
whereas higher doses are commonly used for hormo-
nally active pituitary adenomas. For secreting adenomas,
normalization of hormone hypersecretion is reported in
Table 4 Selected published results of SRS (2000–2015) for the treatment of prolactin-secreting pituitary adenomas
Authors Patients Type dose Follow-up Tumor Biochemical Late toxicity (%)
of SRS (Gy) (months) control (%) remission (%) visual hypopituitarism
Landolt 2000 [124] 20 GK 29 25 85 25 0 NA
Pan L et al., 2000 [125] 128 GK 33 41 99 41 0 NA
Izawa et al., 2000 [85] 15 GK 23.6 16 100 16 0 NA
Feigl et al., 2002 [32] 18 GK 15a 55 94 60 NA 40
Choi et al., 2003 [126] 21 GK 28.5a 42.5 96.9 23.8 0 0
Petrovich et al., 2003 [60] 12 GK 15a 41 83 83 0 4
Pouratian et al., 2006 [127] 23 GK 18.6a 55 89 26 7 28
Voges et al., 2006 [66] 13 LINAC 20 56 100 15.4 4.2 18.3
Pollock et al., 2008 [118] 11 GK 18a 48 100 18 at 4 years 9.1 36
Castinetti et al., 2009 [100] 15 GK 28a 96 100 46.6 0 21
Jezkova et al., 2009 [128] 35 GK 34a 75.5 97 37.1 0 14.3
Wan et al., 2009 [98] 176 GK 22.4a 67.5 90.3 23.3 0 1.8
Tanaka et al., 2010 [129] 22 GK 25a 60 100 18 4 42 at 4 years
Sheehan et al., 2011 [36] 32 GK 24a 31 93 26 2.4 24.4
Liu et al., 2013 [130] 22 GK 15a 36 86 27.3 0 4.5
Wattson et al., 2014 [109] 9 Protons 20 60 98 22 0 57
Cohen-Inbar et al., 2015 [131] 38 GK 25a 42.3 92 50 4.2 30.3
SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
amarginal dose
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more than 50 % of patients at 5 years, being similar for
doses of 20–25 Gy or > 25 Gy. Currently, the optimal
dose to achieve biochemical remission of hormone-
secreting adenomas remains to be determined. The ma-
jority of studies report on the use of GK SRS in patients
with either nonfunctioning or secreting pituitary aden-
omas, whereas only few retrospective series show the re-
sults of LINAC SRS. In the respect of few series, the
reported tumor control, biochemical remission of dis-
ease, and toxicity so far are broadly equivalent.
Hypopituitarism represents the most commonly re-
ported late complication of treatment, whereas the inci-
dence of other late effect radiation complications are
low. In this regard, an accurate delineation of the target
and surrounding structures is mandatory during the
radiosurgical process; future studies need to incorporate
precise dosimetric information of doses delivered to
OARs to better understand the relationship between
doses to OARs and development of hypopituitarism.
A few series suggest that multi-fraction SRS may be an
appropriate treatment in patients with tumors in close
proximity to the optic apparatus; however, the advan-
tages of hypofractionated schedules in terms of local
control and risk of radiation-induced toxicity as com-
pared to single-fraction SRS remains to be proved. For
large pituitary adenomas involving the optic apparatus,
the use of fractionated stereotactic radiotherapy using a
conventional fractionation (45–54 Gy in 25–30 daily
fractions) is recommended. Several studies have shown a
tumor control of 90–95 % for pituitary tumors of any
size, including large or giant tumors, and hormone hy-
persecretion normalization of 50 % at 5 years [132–142].
In clinical practice, single fraction SRS is recom-
mended for small-to-moderate sized pituitary adenomas
(< 2.5–3 cm) even when the adenoma is close to the
optic apparatus as long as the dose to the optic appar-
atus is kept below 8–10 Gy. Fractionated SRS, usually
25 Gy in 5 fractions, may represent a better treatment
option when a single fraction dose carries an unaccept-
able risk of optic neuropathy (as for tumors adiacent the
optic chiasm); however, studies with more patients and
longer follow-up are required to draw definite conclu-
sions. Fractionated stereotactic radiotherapy would be
the recommended radiation treatment modality for le-
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